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BLETTER TO THE EDITOR
apsone-Induced Methemoglobinemia after
ematopoietic Stem Cell Transplantation
b
m
t
w
M
c
t
v
h
m
i
r
e
p
a
s
n
l
o
d
t
a
m
d
v
e
m
c
a
a
c
o
w
d
a
h
p
d
w
S
tWe welcome the recent report of Sangiolo et al.
1] that described the effective use of dapsone as an
lternative to trimethoprim-sulfamethoxazole for
neumocystis jiroveci prophylaxis after hematopoietic
tem cell transplantation (SCT). The toxicities of dap-
one, including hemolysis due to glucose-6-phosphate
ehydrogenase (G6PD) deﬁciency, were well ad-
ressed; however, we do wish to highlight 1 particular
ematologic toxicity associated with dapsone use,
amely, methemoglobinemia. According to a study of
ediatric acute lymphoblastic leukemia (ALL) patients
y Williams et al. [2], methemoglobinemia can occur
n up to 20% (3/15) of pediatric ALL patients taking
apsone. A larger series that examined 2167 patients
ndergoing co-oximetry testing by Ash-Bernal et al.
3] demonstrated a 5.8% incidence of increased met-
emoglobin levels, of which dapsone was identiﬁed as
he cause in 48% of the cases. In the study by Sangiolo
t al. [1], 19 of 155 patients experienced adverse clin-
cal events, none of which the authors described as
ife-threatening. Of these 19 patients, 5 developed
ethemoglobinemia. Although the methemoglobin-
mia in these 5 patients was not considered severe, we
elieve methemoglobinemia to be an important con-
ideration in the treatment of patients receiving pro-
hylactic dapsone, because of its nonspeciﬁc presen-
ation and its potential lethality. We describe 2
atients who were admitted for altered mental status
fter SCT that was ultimately determined to be a
anifestation of dapsone-induced methemoglobin-
mia.
Patient 1 was a 44-year-old white man who pre-
ented with confusion 11 months after a HLA-
atched sibling allogeneic SCT for ALL. The patient
xhibited mild aphasia and difﬁculty with coordina-
ion. Because he had a history of seizures on cyclo-
porine, prophylactic phenytoin was begun. A cranial
omputed tomographic scan was unremarkable. The
ollowing day, the patient developed paresthesias and
lurred speech. A faint, bluish tinge to the patient’s
ail beds was noted. His oxygen saturation levels
ropped into the high 80s, and he became progres-
ively short of breath. Both the patient and the donor
ere negative for G6PD deﬁciency. The patient had t
B&MTeen receiving prophylactic dapsone at a dose of 100
g by mouth once a day for 28 weeks before presen-
ation. Methemoglobinemia secondary to dapsone use
as suspected, and further dapsone was withheld.
ethemoglobin levels were obtained and disclosed a
irculating level of 10.2% (normal 1.5%). The pa-
ient’s methemoglobinemia was reversed by the intra-
enous administration of 1 mg/kg methylene blue, and
is respiratory status improved from requiring supple-
ental oxygen to room air in less than an hour, reach-
ng saturations of 96% to 97%. His mental status
eturned to baseline upon reversal of methemoglobin-
mia.
Patient 2 was a 44-year-old white woman who
resented 18 months after an HLA-matched sibling
llogeneic SCT for aplastic anemia with confusion,
evere chest congestion, chest discomfort, and short-
ess of breath. She was found to have a fever and left
ower lobe crackles, as well as tachypnea and cyanosis
n physical examination. Both the patient and the
onor were negative for G6PD deﬁciency. The pa-
ient had been taking dapsone 100 mg/d by mouth for
t least 10 weeks before presentation. The patient’s
ethemoglobin level was 9.7%; dapsone was then
iscontinued, and her methemoglobinemia was re-
ersed with intravenous infusion of 1 mg/kg methyl-
ne blue. She also completed further therapy with
etronidazole for a concomitant pneumonia. Typi-
ally, reports of methemoglobinemia have been
round the fourth to sixth week after starting dapsone,
nd most are not dose related [3-5]. Our patients, by
ontrast, had been taking dapsone for a longer period
f time before presentation: 28 and 10 weeks. Of note,
e did not observe a relationship between dapsone
osing and the development of methemoglobinemia,
nd this is consistent with previous reports.
We draw attention to dapsone’s induction of met-
emoglobinemia because of the relatively nonspeciﬁc
resentation that can be initially confused with car-
iopulmonary or central nervous system disease. As
ith both of the patients described, many allogeneic
CT patients are taking multiple medications for
ransplant-related comorbidities that can confound
he presentation of methemoglobinemia. This can
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2ead to a delay in diagnosis that could progress to a
tate of hypoxic-induced cell damage if the condition
s untreated. The recognition of methemoglobinemia
s further complicated by the lack of pathognomonic
ymptoms and signs. Its “classic” presentations, short-
ess of breath and confusion, are manifestations of
everal other conditions. Anemia, a frequent presence
n the posttransplantation patient, worsens these man-
festations. Therefore, awareness of this toxicity by the
linical team is crucial.
Several studies have warned against the use of
tandard pulse oximetry to screen for methemoglobin-
mia, because this method cannot distinguish between
arious types of hemoglobin [3]. Increased methemo-
lobin levels can skew pulse oximetry readings, thus
eading to a discrepancy between oxygen saturation
evels taken from pulse oximetry and those derived
rom the arterial blood gas. The existence of such a
saturation gap” between pulse oximetry and arterial
lood gas levels requires further investigation into the
omposition of a patient’s circulating hemoglobin.
o-oximetry is a sensitive, cost-effective, and rela-
ively noninvasive test that should be used to conﬁrm
he presence of increased methemoglobin levels in
atients who present with altered mental status and
emonstrate a saturation gap [3,6-8]. It should be
oted that reversal with methylene blue may cause
ebound methemoglobinemia, thus necessitating se-
ial measurements to verify a decrease in methemo-
lobin levels [9,10].
Numerous retrospective studies and case reports
ave discussed drug-induced methemoglobinemia,
rimarily in patients with malaria and leprosy, patients
fter solid-organ transplantations, and patients receiv-
ng topical benzocaine [3-5,10,11]. As noted, accord-
ng to a review of 2167 patients undergoing co-oxim-
try reported by Ash-Bernal et al. [3], dapsone was by
ar the most common causative agent. This commu-
ication is the ﬁrst report of 2 patients with dapsone-
nduced methemoglobinemia after hematopoietic
CT. Because methemoglobin levels are not routinely
eported as part of arterial blood gas determinations,
he diagnosis of methemoglobinemia in these 2 pa-
ients would have been delayed if not for heightened
linical awareness and suspicion. We recommend
creening with co-oximetry for methemoglobinemia
n any patient taking dapsone who presents with an
ltered mental status, with or without shortness of
R
B
42reath and cyanosis, especially upon detection of a
aturation gap.
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